Drug repurposing, Big Data & Artificial Intelligence

Lay science article about drug repurposing published in InScience Magazine. Drug repurposing significantly accelerates the discovery and development of drugs with a substantial impact on rare diseases. In collaboration with big data and artificial intelligence (AI) technologies, it enhances the reliability of predictions, regarding the effectiveness, but also the toxicity of the repurposed drug. Modern computational tools now guide and enrich laboratory approaches, while the latter validate working hypotheses or create new ones. A typical example of innovative synergies is the drug repositioning platform Cloudscreen©, an innovation product of Cloudpharm PC, a Greek start-up company, and the Biomarker Discovery & Translational Research Laboratory of the National Research Foundation.

Three-Dimensional Cell Metabolomics Deciphers the Anti-Angiogenic Properties of the Radioprotectant Amifostine

Three-Dimensional Cell Metabolomics Deciphers the Anti-Angiogenic Properties of the Radioprotectant Amifostine

Abstract

Aberrant angiogenesis is a hallmark for cancer and inflammation, a key notion in drug repurposing efforts. To delineate the anti-angiogenic properties of amifostine in a human adult angiogenesis model via 3D cell metabolomics and upon a stimulant-specific manner, a 3D cellular angiogenesis assay that recapitulates cell physiology and drug action was coupled to untargeted metabolomics by liquid chromatography–mass spectrometry and nuclear magnetic resonance spectroscopy. The early events of angiogenesis upon its most prominent stimulants (vascular endothelial growth factor-A or deferoxamine) were addressed by cell sprouting measurements. Data analyses consisted of a series of supervised and unsupervised methods as well as univariate and multivariate approaches to shed light on mechanism-specific inhibitory profiles. The 3D untargeted cell metabolomes were found to grasp the early events of angiogenesis. Evident of an initial and sharp response, the metabolites identified primarily span amino acids, sphingolipids, and nucleotides. Profiles were pathway or stimulant specific. The amifostine inhibition profile was rather similar to that of sunitinib, yet distinct, considering that the latter is a kinase inhibitor. Amifostine inhibited both. The 3D cell metabolomics shed light on the anti-angiogenic effects of amifostine against VEGF-A- and deferoxamine-induced angiogenesis. Amifostine may serve as a dual radioprotective and anti-angiogenic agent in radiotherapy patients.

Drug repurposing in Glioblastoma Multiforme

Drug repurposing in Glioblastoma Multiforme

Poster presenation at 1st ESN-ISN School “FROM NEURODEGENERATION TO NEURAL CARCINOGENESIS: MECHANISMS AND COMMON BIOLOGIES” and the 10th International Hellenic Crystallographic Association Conference